Cargando…
Decidual stromal cell therapy for generalized lymphadenopathy as a special clinical manifestation of COVID‐19 infection: A case report
We are going through the greatest global health crisis of the last decades, the coronavirus disease 2019 (COVID‐19) pandemic. It may cause morbidity and mortality in some cases, and there is no therapeutic approach with reproducible and favorable outcomes. As clinical manifestations differ from pati...
Autores principales: | Pirsalehi, Ali, Soleimani, Masoud, Hajifathali, Abbas, Sadeghi, Behnam, Farhadihosseinabadi, Behrouz, Akhlaghi, Sedigheh Sadat, Roshandel, Elham |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109646/ https://www.ncbi.nlm.nih.gov/pubmed/35600010 http://dx.doi.org/10.1002/ccr3.5851 |
Ejemplares similares
-
Conquering the cytokine storm in COVID‐19‐induced ARDS using placenta‐derived decidua stromal cells
por: Sadeghi, Behnam, et al.
Publicado: (2021) -
Mesenchymal stromal cell-derived secretome-based therapy for neurodegenerative diseases: overview of clinical trials
por: Ghasemi, Maryam, et al.
Publicado: (2023) -
Post‐hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors
por: Roshandel, Elham, et al.
Publicado: (2022) -
Vasculopathy-related cutaneous lesions and intrahepatic cholestasis as synchronous manifestations in a COVID-19 patient; a case report
por: Sadeghi, Amir, et al.
Publicado: (2020) -
Plasma exchange followed by convalescent plasma transfusion in COVID-19 patients
por: Roshandel, Elham, et al.
Publicado: (2021)